Scenario 3: A 44-Year-Old Woman With RCC at Intermediate-Hig

Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.

Related Keywords

, Optimizing Outcomes , Patients With , Translating Evidence , Clinical Practice , Year Old Woman With , Intermediate High Risk , Renal Cell Carcinoma , Nrcc , Kidney Cancer , Pembrolizumab , Adjuvant Pembrolizumab , Trio Therapy , Immune Checkpoint Inhibitors , Keynote 564 , Prosper Trial , Prosper Study , Immotion010 , Atezolizumab , Nivolumab , Ipilimumab , Combination Therapy , Novel Therapy , Risk Of Recurrence , Risk For Recurrence , Recurrence Risk ,